192 related articles for article (PubMed ID: 36567327)
1. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the "Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)" project.
Kyou Y; Yasui-Furukori N; Hasegawa N; Ide K; Ichihashi K; Hashimoto N; Hori H; Shimizu Y; Imamura Y; Muraoka H; Iida H; Ohi K; Yasuda Y; Ogasawara K; Numata S; Iga JI; Tsuboi T; Ochi S; Kodaka F; Furihata R; Onitsuka T; Makinodan M; Komatsu H; Takeshima M; Kubota C; Hishimoto A; Atake K; Yamagata H; Kido M; Nagasawa T; Usami M; Kishimoto T; Kikuchi S; Matsumoto J; Miura K; Yamada H; Watanabe K; Inada K; Hahimoto R
Ann Gen Psychiatry; 2022 Dec; 21(1):52. PubMed ID: 36567327
[TBL] [Abstract][Full Text] [Related]
2. The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project.
Ichihashi K; Kyou Y; Hasegawa N; Yasui-Furukori N; Shimizu Y; Hori H; Hashimoto N; Ide K; Imamura Y; Yamada H; Ochi S; Iga JI; Takaesu Y; Ohi K; Tsuboi T; Iida H; Yamagata H; Hishimoto A; Horai T; Usami M; Makinodan M; Nagasawa T; Komatsu H; Kido M; Muraoka H; Atake K; Takeshima M; Kubota C; Inagaki T; Tamai S; Kishimoto T; Furihata R; Matsumoto J; Miura K; Inada K; Watanabe K; Kasai K; Hashimoto R
Asian J Psychiatr; 2022 Mar; 69():103007. PubMed ID: 35051727
[TBL] [Abstract][Full Text] [Related]
3. Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project.
Hashimoto N; Yasui-Furukori N; Hasegawa N; Ishikawa S; Hori H; Iida H; Ichihashi K; Miura K; Matsumoto J; Numata S; Kodaka F; Furihata R; Ohi K; Ogasawara K; Iga JI; Muraoka H; Komatsu H; Takeshima M; Atake K; Kido M; Nakamura T; Kishimoto T; Hishimoto A; Onitsuka T; Okada T; Ochi S; Nagasawa T; Makinodan M; Yamada H; Tsuboi T; Yamada H; Inada K; Watanabe K; Hashimoto R
BMC Psychiatry; 2023 Jun; 23(1):473. PubMed ID: 37380997
[TBL] [Abstract][Full Text] [Related]
4. Influence of Psychotropic
Kyou Y; Oishi S; Takizawa T; Yoshimura Y; Hashimoto I; Suzuki R; Demizu R; Ono T; Noguchi Y; Kimura T; Inada K; Miyaoka H
Clin Psychopharmacol Neurosci; 2023 May; 21(2):332-339. PubMed ID: 37119226
[TBL] [Abstract][Full Text] [Related]
5. The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study.
Nakamura T; Furihata R; Hasegawa N; Kodaka F; Muraoka H; Ichihashi K; Ochi S; Numata S; Tsuboi T; Makinodan M; Iida H; Onitsuka T; Kashiwagi H; Takeshima M; Hashimoto N; Nagasawa T; Usami M; Yamagata H; Takaesu Y; Miura K; Matsumoto J; Ohi K; Yamada H; Hori H; Inada K; Watanabe K; Hashimoto R; Yasui-Furukori N
BMC Psychiatry; 2024 May; 24(1):399. PubMed ID: 38807065
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project.
Hashimoto N; Yasui-Furukori N; Hasegawa N; Ishikawa S; Numata S; Hori H; Iida H; Ichihashi K; Furihata R; Murata A; Tsuboi T; Takeshima M; Kyou Y; Komatsu H; Kubota C; Ochi S; Takaesu Y; Usami M; Nagasawa T; Hishimoto A; Miura K; Matsumoto J; Ohi K; Yamada H; Inada K; Watanabe K; Shimoda K; Hashimoto R
Asian J Psychiatr; 2021 Sep; 63():102744. PubMed ID: 34325252
[TBL] [Abstract][Full Text] [Related]
7. As-Needed Prescribing and Administration of Psychotropic Medications in Assisted Living: A 7-State Study.
Carder P; Zimmerman S; Wretman CJ; Preisser JS; Dys S; Sloane PD
J Am Med Dir Assoc; 2022 Jun; 23(6):1038-1044.e3. PubMed ID: 34919835
[TBL] [Abstract][Full Text] [Related]
8. Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study.
Hasegawa N; Yasuda Y; Yasui-Furukori N; Yamada H; Hori H; Ichihashi K; Takaesu Y; Iida H; Muraoka H; Kodaka F; Iga JI; Hashimoto N; Ogasawara K; Ohi K; Fukumoto K; Numata S; Tsuboi T; Usami M; Hishimoto A; Furihata R; Kishimoto T; Nakamura T; Katsumoto E; Ochi S; Nagasawa T; Atake K; Kubota C; Komatsu H; Yamagata H; Ide K; Takeshima M; Kido M; Kikuchi S; Okada T; Matsumoto J; Miura K; Shimazu T; Inada K; Watanabe K; Hashimoto R
Psychiatry Clin Neurosci; 2023 Oct; 77(10):559-568. PubMed ID: 37684711
[TBL] [Abstract][Full Text] [Related]
9. Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project.
Ichihashi K; Hori H; Hasegawa N; Yasuda Y; Yamamoto T; Tsuboi T; Iwamoto K; Kishimoto T; Horai T; Yamada H; Sugiyama N; Nakamura T; Tsujino N; Nemoto K; Oishi S; Usami M; Katsumoto E; Yamamori H; Tomita H; Suwa T; Furihata R; Inagaki T; Fujita J; Onitsuka T; Miura K; Matsumoto J; Ohi K; Matsui Y; Takaesu Y; Hashimoto N; Iga J; Ogasawara K; Yamada H; Watanabe K; Inada K; Hashimoto R
Neuropsychopharmacol Rep; 2020 Sep; 40(3):281-286. PubMed ID: 32602667
[TBL] [Abstract][Full Text] [Related]
10. Pro re nata medication for psychoses: an audit of practice in two metropolitan hospitals.
Geffen J; Sorensen L; Stokes J; Cameron A; Roberts MS; Geffen L
Aust N Z J Psychiatry; 2002 Oct; 36(5):649-56. PubMed ID: 12225449
[TBL] [Abstract][Full Text] [Related]
11. Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study.
Ochi S; Tagata H; Hasegawa N; Yasui-Furukori N; Iga JI; Kashiwagi H; Kodaka F; Komatsu H; Tsuboi T; Tokutani A; Numata S; Ichihashi K; Onitsuka T; Muraoka H; Iida H; Ohi K; Atake K; Kishimoto T; Hori H; Takaesu Y; Takeshima M; Usami M; Makinodan M; Hashimoto N; Fujimoto M; Furihata R; Nagasawa T; Yamada H; Matsumoto J; Miura K; Kido M; Hishimoto A; Ueno SI; Watanabe K; Inada K; Hashimoto R
Int J Neuropsychopharmacol; 2022 Oct; 25(10):818-826. PubMed ID: 35723038
[TBL] [Abstract][Full Text] [Related]
12. Prescription of potentially inappropriate psychotropic drugs in homeless people with schizophrenia and bipolar disorders. Results from the French Housing First (FHF) program.
Fond G; Tinland A; Boucekine M; Girard V; Loubière S; Auquier P; Boyer L;
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():84-89. PubMed ID: 30153497
[TBL] [Abstract][Full Text] [Related]
13. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.
Furihata R; Otsuki R; Hasegawa N; Tsuboi T; Numata S; Yasui-Furukori N; Kashiwagi H; Hori H; Ochi S; Muraoka H; Onitsuka T; Komatsu H; Takeshima M; Hishimoto A; Nagasawa T; Takaesu Y; Nakamura T; Asami T; Miura K; Matsumoto J; Ohi K; Yasuda Y; Iida H; Ogasawara K; Hashimoto N; Ichihashi K; Yamada H; Watanabe K; Inada K; Hashimoto R
Sleep Med; 2022 Jan; 89():23-30. PubMed ID: 34875519
[TBL] [Abstract][Full Text] [Related]
14. Development of individual fitness score for conformity of prescriptions to the "Guidelines For Pharmacological Therapy of Schizophrenia".
Inada K; Fukumoto K; Hasegawa N; Yasuda Y; Yamada H; Hori H; Ichihashi K; Iida H; Ohi K; Muraoka H; Kodaka F; Ide K; Hashimoto N; Iga JI; Ogasawara K; Atake K; Takaesu Y; Nagasawa T; Komatsu H; Okada T; Furihata R; Kido M; Kikuchi S; Kubota C; Makinodan M; Ochi S; Takeshima M; Yamagata H; Matsumoto J; Miura K; Usami M; Kishimoto T; Onitsuka T; Katsumoto E; Hishimoto A; Numata S; Yasui-Furukori N; Watanabe K; Hashimoto R
Neuropsychopharmacol Rep; 2022 Dec; 42(4):502-509. PubMed ID: 36254805
[TBL] [Abstract][Full Text] [Related]
15. Pro re nata medications in mental health: Results of a transversal study.
Legrand G; Gregoire E; Fererol D; Cardinaud Z; Cussac-Buchdahl C; Debost-Legrand A
Encephale; 2023 Jun; 49(3):268-274. PubMed ID: 36253181
[TBL] [Abstract][Full Text] [Related]
16. Use of Psychotropic "Pro Re Nata" Medications by Patients Attending the Outpatient Clinic in a Hospital: A Qualitative Exploration.
Rajiah K; Maharajan MK; Ramaya H; Wan Ab Rahman WNA
Front Med (Lausanne); 2021; 8():617147. PubMed ID: 34368172
[No Abstract] [Full Text] [Related]
17. Pro re nata medication for psychiatric inpatients: time to act.
Hilton MF; Whiteford HA
Aust N Z J Psychiatry; 2008 Jul; 42(7):555-64. PubMed ID: 18612858
[TBL] [Abstract][Full Text] [Related]
18. Use of pro re nata medications in acute inpatient care.
Stein-Parbury J; Reid K; Smith N; Mouhanna D; Lamont F
Aust N Z J Psychiatry; 2008 Apr; 42(4):283-92. PubMed ID: 18330770
[TBL] [Abstract][Full Text] [Related]
19.
Saito E; Eng S; Grosso C; Ozinci Z; Van Meter A
J Child Adolesc Psychopharmacol; 2020 May; 30(4):250-260. PubMed ID: 31800304
[No Abstract] [Full Text] [Related]
20. PRN Medicines Management for Psychotropic Medicines in Long-Term Care Settings: A Systematic Review.
Vaismoradi M; Vizcaya Moreno F; Sletvold H; Jordan S
Pharmacy (Basel); 2019 Nov; 7(4):. PubMed ID: 31775262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
